The University of Texas MD Anderson Cancer Center (MDACC) has initiated an investigator-initiated clinical trial of an investigational drug for late stage pancreatic cancer called SOR-C13.
Developed by Toronto, Canada-based Soricimed Biopharma, Inc., a clinical-stage emerging biopharma venture, MDACC will conduct a Phase I investigator-initiated trial led by Siqing Fu, MD PhD, a member of the Department of Investigational Cancer Therapeutics at MDACC, one of the world’s most respected cancer research centers.
The Phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
An investigator-initiated trial, MDACC, has targeted 36 participants for a study that will complete August 2022. The objectives of the Phase Ib study are to refine dosing and further explore safety and efficacy of SOR-C13 in late-stage solid tumor cancer.
What is SOR-C13?
It is a selective inhibitor of TRPV6, a calcium oncochannel over-expressed by solid tumor cancers. SOR-C13 binds with high affinity and selectivity and disrupts the function of TRPV6. TRPV6 plays a vital role in biochemical cascade that results in the upregulation of an array of pro-cancerous genes. TRPV6 is considered to be an important target for novel anticancer therapy. SOR-C13 is the first highly specific TRPV6 inhibitor to be identified and taken into clinical development.
Who is Soricimed Biopharma?
A privately-held, clinical-stage, emerging biopharmaceutical company focused on developing first-in-class targeted cancer therapies. Their lead candidate SOR-C13 was shown to be safe and well-tolerated with over half of the patients treated having stable disease after 2 treatment cycles. Two patients with stage IV pancreatic cancer showed tumor size reduction with one patient achieving a 30% reduction in the size of the primary pancreatic cancer tumor. The FDA has granted orphan-drug designation to SOR-C13.
Call to Action: This investigator-initiated study will determine with more specificity the promise of SOR-C13. Those that have a loved one with pancreatic cancer may want to monitor this study or connect with MD Anderson as they represent one of the most elite cancer research centers in the world. We offer a link to the principal investigator’s profile, and we can also broker a connection for those interested.